Detection of Staphylococcus aureus isolates with heterogeneous intermediate-level resistance to vancomycin in the United States

Journal of Clinical Microbiology

Volumn 49, Issue 12, 2011, Pages 4203-4207

  Richter, Sandra S ^a   Satola, Sarah W ^b,c   Crispell, Emily K ^c,d   Heilmann, Kristopher P ^e   Dohrn, Cassie L ^e   Riahi, Fathollah ^e   Costello, Andrew J ^e   Diekema, Daniel J ^e   Doern, Gary V ^e  

^a LERNER RESEARCH INSTITUTE   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c ATLANTA VA MEDICAL CENTER   (United States)

^d ATLANTA RESEARCH AND EDUCATION FOUNDATION   (United States)

^e UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFTAROLINE; CLINDAMYCIN; COTRIMOXAZOLE; DAPTOMYCIN; ERYTHROMYCIN; LEVOFLOXACIN; LINEZOLID; OXACILLIN; TEICOPLANIN; TIGECYCLINE; VANCOMYCIN;

ANALYTIC METHOD; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIAL VIABILITY; BACTERIUM DETECTION; BACTERIUM EXAMINATION; BACTERIUM ISOLATE; BROTH DILUTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; EPSILOMETER TEST; GENETIC VARIABILITY; HETERORESISTANT VANCOMYCIN INTERMEDIATE STAPHYLOCOCCUS AUREUS; INCUBATION TIME; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; POPULATION ANALYSIS PROFILING AREA UNDER THE CURVE; PREDICTIVE VALUE; PRIORITY JOURNAL; PULSED FIELD GEL ELECTROPHORESIS; REPRODUCIBILITY; STAPHYLOCOCCUS AUREUS; UNITED STATES;

ANTI-BACTERIAL AGENTS; HUMANS; MICROBIAL SENSITIVITY TESTS; PREVALENCE; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; TEICOPLANIN; UNITED STATES; VANCOMYCIN; VANCOMYCIN RESISTANCE;

EID: 82455185169     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.01152-11     Document Type: Article

References (28)

1. Adam, H. J., et al. 2010. Detection and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates in Canada: results from the Canadian nosocomial infection surveillance program, 1995-2006. Antimicrob. Agents Chemother. 54:945-949.
2. Charles, P. G., P. B. Ward, P. D. Johnson, B. P. Howden, and M. L. Grayson. 2004. Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus. Clin. Infect. Dis. 38:448-451. (Pubitemid 38200128)
3. Clinical and Laboratory Standards Institute. 2009. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, 8th ed. CLSI document M7-A8. CLSI, Wayne, PA.
4. Clinical and Laboratory Standards Institute. 2009. Performance standards for antimicrobial susceptibility testing; 19th informational supplement. CLSI document M100-S19. CLSI, Wayne, PA.
5. Garnier, F., et al. 2006. A 1 year surveillance study of glycopeptide-intermediate Staphylococcus aureus strains in a French hospital. J. Antimicrob. Agents Chemother. 57:146-149. (Pubitemid 43057073)
6. Hiramatsu, K. 2001. Vancomycin-resistant Staphylococcus aureus: a new model of antibiotic resistance. Lancet Infect. Dis. 1:147-155. (Pubitemid 33586048)
7. Hiramatsu, K., et al. 1997. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet 350:1670-1673. (Pubitemid 28036828)
8. Horne, K. C., et al. 2009. Prospective comparison of the clinical impacts of heterogeneous vancomycin-intermediate methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-susceptible MRSA. Antimicrob. Agents Chemother. 53:3447-3452.
9. Howden, B. P., J. K. Davies, P. D. Johnson, T. P. Stinear, and M. L. Grayson. 2010. Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications. Clin. Microbiol. Rev. 23:99-139.
10. Ike, Y., et al. 2001. Nationwide survey shows that methicillin-resistant Staphylococcus aureus strains heterogeneously and intermediately resistant to vancomycin are not disseminated throughout Japanese hospitals. J. Clin. Microbiol. 39:4445-4451. (Pubitemid 33117137)
11. Khosrovaneh, A., et al. 2004. Frequency of reduced vancomycin susceptibility and heterogeneous subpopulation in persistent or recurrent methicillinresistant Staphylococcus aureus bacteremia. Clin. Infect. Dis. 38:1328-1330. (Pubitemid 38608580)
12. Kollef, M. H. 2007. Limitations of vancomycin in the management of resistant staphylococcal infections. Clin. Infect. Dis. 45:S191-S195. (Pubitemid 47378906)
13. Leonard, S. N., K. L. Rossi, K. L. Newton, and M. J. Rybak. 2009. Evaluation of the Etest GRD for the detection of Staphylococcus aureus with reduced susceptibility to glycopeptides. J. Antimicrob. Chemother. 63:489-492.
14. Lina, G., et al. 1999. Involvement of Panton-Valentine leukocidin-producing Staphylococcus aureus in primary skin infections and pneumonia. Clin. Infect. Dis. 29:1128-1132. (Pubitemid 30265628)
15. Liu, C., et al. 2011. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin. Infect. Dis. 52:e18-e55.
16. Lodise, T. P., et al. 2008. Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob. Agents Chemother. 52:3315-3320.
17. McDougal, L. K., et al. 2003. Pulsed-field gel electrophoresis typing of oxacillin-resistant Staphylococcus aureus isolates from the United States: establishing a national database. J. Clin. Microbiol. 41:5113-5120. (Pubitemid 37429924)
18. Mendes, R. E., et al. 2007. Rapid detection and identification of metallo-β-lactamase-encoding genes by multiplex real-time PCR assay and melt curve analysis. J. Clin. Microbiol. 45:544-547.
19. Moore, M. R., F. Perdreau-Remington, and H. F. Chambers. 2003. Vancomycin treatment failure associated with heterogeneous vancomycin-intermediate Staphylococcus aureus in a patient with endocarditis and in the rabbit model of endocarditis. Antimicrob. Agents Chemother. 47:1262-1266. (Pubitemid 36368583)
20. Oliveira, D. C., and H. de Lencastré. 2002. Multiplex PCR strategy for rapid identification of structural types and variants of the mec element in methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 46:2155-2161. (Pubitemid 34665910)
21. Pfaller, M. A., A. M. Caliendo, and J. Versalovic. 2010. Chromosomal restriction fragment analysis by pulsed-field gel electrophoresis: application to molecular epidemiology, p. 12.4.5.1-12.4.5.7. In L. S. Garcia (ed.), Clinical microbiology procedures handbook, 3rd ed. ASM Press, Washington, DC.
22. Pfeltz, R. F., J. L. Schmidt, and B. J. Wilkinson. 2001. A microdilution plating method for population analysis of antibiotic-resistant staphylococci. Microb. Drug Resist. 7:289-295. (Pubitemid 33104604)
23. Richter, S. S., et al. 2011. Activity of ceftaroline and epidemiologic trends in Staphylococcus aureus isolates collected from 43 medical centers in the United States in 2009. Antimicrob. Agents Chemother. 55:4154-4160.
24. Sancak, B., S. Ercis, D. Menemenlioglu, S. Colakoglu, and G. Hascelik. 2005. Methicillin-resistant Staphylococcus aureus heterogeneously resistant to vancomycin in a Turkish university hospital. J. Antimicrob. Chemother. 56:519-523. (Pubitemid 41264130)
25. Satola, S. W., A. M. Caliendo, M. M. Farley, J. B. Patel, and E. M. Burd. 2009. Lack of heteroresistance among Staphylococcus aureus isolates with vancomycin MICs of 2 micrograms per milliliter by automated testing. J. Clin. Microbiol. 47:2680-2681.
26. Satola, S. W., M. M. Farley, K. F. Anderson, and J. B. Patel. 2011. Comparison of detection methods for heteroresistant vancomycin-intermediate Staphylococcus aureus with the population analysis profile method as the reference method. J. Clin. Microbiol. 49:177-183.
27. Wootton, M., et al. 2001. A modified population analysis profile (PAP) method to detect hetero-resistance to vancomycin in Staphylococcus aureus in a UK hospital. J. Antimicrob. Chemother. 47:399-404.
28. Yusof, A., et al. 2008. Evaluation of a new Etest vancomycin-teicoplanin strip for detection of glycopeptide-intermediate Staphylococcus aureus (GISA), in particular, heterogeneous GISA. J. Clin. Microbiol. 46:3042-3047.